Sign in

AGMB on Nasdaq

AgomAb Therapeutics NV

In its 2026 annual report (Form 20-F) the company says: “We are a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for fibro-inflammatory diseases with high unmet medical need. We have assembled an executive team with deep scientific and clinical development expertise and a track record of strong business leadership.”3 Its shares trade on Nasdaq under the symbol AGMB.1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with another stock.

  • TickerAGMB on Nasdaq1
  • IndustryBiological Products, (No Diagnostic Substances)1
  • HeadquartersC91
  • Incorporated inBelgium2
  • Business addressPosthoflei 1/6, Antwerpen, 26002
  • Filer categoryNon-accelerated filer, Emerging growth company2

See how the biggest companies compare on our leaderboards

We are a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for fibro-inflammatory diseases with high unmet medical need.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Every line of the income statement as filed: the last 3 fiscal years, latest first.4

Period ending2025-12-312024-12-312023-12-31
Research and development expenses-48.9M EUR-39.3M EUR-26.3M EUR
General and administrative expenses-12.8M EUR-10.1M EUR-6.1M EUR
Total operating expenses-61.7M EUR-49.4M EUR-32.4M EUR
Other operating income2.4M EUR1.4M EUR1.2M EUR
Operating loss-59.3M EUR-48.0M EUR-31.2M EUR
Changes in fair value of financial liabilities-4.9M EUR848.0K EUR19.0M EUR
Financial expenses-133.0K EUR-357.0K EUR-86.0K EUR
Financial income1.7M EUR1.3M EUR303.0K EUR
Loss before taxes-62.5M EUR-46.3M EUR-12.0M EUR
Income tax (expense)/income-4.0K EUR619.0K EUR
Loss for the year-62.5M EUR-46.3M EUR-11.4M EUR
Weighted average number of common shares outstanding, Basic541.1K shares541.1K shares541.1K shares
Weighted average number of common shares outstanding, Diluted541.1K shares541.1K shares541.1K shares
Basic loss per share (in )-143.22 EUR-107.09 EUR-35.63 EUR
Diluted loss per share (in )-143.22 EUR-107.09 EUR-35.63 EUR

Compare AgomAb Therapeutics NV with another company

Corporate structure

AgomAb Therapeutics NV sits at the top of its group. 1 entity on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of AgomAb Therapeutics NV

  • AgomAb Therapeutics NV C9

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

Leadership

Who has led AgomAb Therapeutics NV, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Tim Jasper Knotnerus2026–now

Chief financial officer

  1. Pierre Thadee Victor Kemula2026–now
Board members and other officers (11)

Timeline

  1. Mar 18, 2026New chief executive Tim Jasper Knotnerus becomes CEO5

Filings

47 filings to the SEC since October 2021: 1 annual reports, 19 insider forms, 6 large holders, 21 other. The latest 20:

  1. Oct 13, 20266-K EDGAR
  2. Oct 9, 20264 PRIMARY DOCUMENT EDGAR
  3. Oct 7, 20264 PRIMARY DOCUMENT EDGAR
  4. Oct 7, 20264 PRIMARY DOCUMENT EDGAR
  5. Oct 7, 20264 PRIMARY DOCUMENT EDGAR
  6. Oct 1, 20266-K EDGAR
  7. Sep 15, 20264 OWNERSHIP DOCUMENT EDGAR
  8. Sep 15, 20264 OWNERSHIP DOCUMENT EDGAR
  9. Sep 15, 20263 OWNERSHIP DOCUMENT EDGAR
  10. Sep 15, 20263 OWNERSHIP DOCUMENT EDGAR
  11. Sep 14, 20266-K EDGAR
  12. Sep 11, 20266-K EDGAR
  13. Aug 10, 20266-K EDGAR
  14. Aug 6, 20266-K EDGAR
  15. Jun 23, 20266-K EDGAR
  16. May 27, 20266-K EDGAR
  17. May 15, 2026SCHEDULE 13G EDGAR
  18. May 15, 2026SCHEDULE 13G EDGAR
  19. May 6, 2026SCHEDULE 13G EDGAR
  20. Apr 24, 20266-K EDGAR

The 47 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 34. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
EQT Fund Management S.a r.l.5,141,992$66.7M7.7%No change
Nantahala Capital Management, LLC3,136,376$40.7M1.2%+1,936,376
Sanofi2,783,096$36.1M6.8%No change
Redmile Group, LLC2,733,926$35.5M2.4%+2,577,676
Cormorant Asset Management, LP2,465,348$32.0M1.6%No change
TCG Crossover Management, LLC2,053,233$26.7M0.6%No change
Federated Hermes, Inc.1,618,000$21.0M0.0%No change
Casdin Capital, LLC1,550,000$20.1M1.0%No change
Andera Partners1,538,702$20.0M9.7%No change
Fmr LLC1,458,677$18.9M0.0%No change
Aberdeen Group plc846,695$11.0M0.0%+139,039
Perceptive Advisors LLC600,000$7.8M0.1%No change
Samsara Biocapital, LLC600,000$7.8M0.6%No change
Siren, L.L.C.411,250$5.3M0.1%No change
Orbimed Advisors LLC192,740$2.5M0.0%New
Pfizer Inc75,000$1.0M0.6%No change
Alps Advisors Inc49,984$648.8K0.0%New
Bellevue Group AG49,248$639.2K0.0%−752
Seven Grand Managers, LLC47,600$617.8K0.0%−152,400
Sectoral Asset Management Inc43,500$564.6K0.4%No change
Burkehill Global Management, LP35,000$454.3K0.0%No change
Quadrature Capital Ltd20,461$265.6K0.0%New
Two Sigma Investments, LP18,072$234.6K0.0%+3,831
Goldman Sachs Group Inc11,800$153.2K0.0%−23,939
XTX Topco Ltd10,271$133.3K0.0%New

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How AgomAb Therapeutics NV is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARAgomAb Therapeutics NV1
  • CIK0002020932
  • Filer statusNon-accelerated filer an emerging growth company; not a shell company3
  • Incorporated inBelgium3
  • Fiscal year endsDecember 311
  • Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business addressPosthoflei 1/6, Antwerpen, 2600, Belgium1
  • Phone32 3 302 35 301
  • Shares outstanding34,167,168 shares as of Dec 31, 20253
  • AuditorDidier Delanoye, Diegem, Belgium PCAOB ID 1350; no auditor attestation of internal control over financial reporting3
  • On EDGAR sinceJun 20, 20241
  • Filings47 in all: 3 (13), 6-K (11), 4 (6), SCHEDULE 13G (5), DRS/A (2), 20-F (1), 424B4 (1), 8-A12B (1)1
    All 15 form types

    CERT (1), DRS (1), EFFECT (1), F-1 (1), F-1/A (1), S-8 (1), SCHEDULE 13D (1)

  • Latest filingsAnnual report (20-F) Apr 23, 2026

Securities registered for trading

ClassSymbolExchange
American Depositary Shares, each representing one common share, no nominal value per shareAGMBNasdaq

From the cover page of the 20-F filed Apr 23, 2026 (Section 12(b) of the Exchange Act).3

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22